APIs and Excipients

Additional reactor capacity and a wastewater processing plant increase API manufacturing capacity at the Cambrex site in Kalskoga, Sweden.

ADC Bio announces plans to expand into clinical and commercial drug manufacturing for ADCs.

BASF will build a new specialty amines plant at its existing wholly owned site in Nanjing Chemical Industry Park in China.

Ajinomoto Althea opens manufacturing suites in new high potency and antibody drug conjugate commercial facility.

Modeling tools help process engineers optimize a biopharmaceutical facility’s capacity.

Drug repurposing, repositioning, and rescue can be faster, cheaper, and target more diseases than traditional drug discovery approaches.

Roquette has completed its previously announced acquisition of Itacel, an excipient division of Blanver.

Informatics software can be used to address the challenges of quality by design, such as managing impurity data when developing an impurity control strategy.

Functionalized calcium carbonate provides high porosity, which enables fast disintegration, and excellent compactibility that results in harder tablets at low compression forces.

Innovative new technologies released over the past several months seek to enhance bio/pharmaceutical development and manufacturing. 

The private investment firm’s $110-million acquisition boosts its API and finished dosage form value chain.

Cambrex is investing $24 Million in new, highly potent API manufacturing capacity at its Charles City, Iowa site.

Featuring software, parallel automated reactors, and other tools designed to facilitate design of experiments, development of the design space, and better process understanding and control, the Hyderabad facility came online on July 20

Media manufacturers are focused on reducing risk, improving quality and consistency, and managing costs.

Managing and prioritizing risk is essential to ensuring raw material quality. USP is developing new guidelines to make the work easier.

Horizon to make publicly available its complete annotated CHO cell-line sequence in hopes of driving bioproduction cell-line innovation.

The addition of 20,000 sq. ft. of manufacturing and office space increases Avecia’s Milford, Ma, oligonucleotide capacity to 3.0 mol.

Cannabinoids have potential to treat a variety of diseases, but pharmaceutical companies must first develop cost-effective ways to access pharmaceutically pure materials without marijuana cultivation.

A Supreme Court decision and improvements in analytical processes may speed the biosimilar approval process.

Poly(lactide-glycolide) has been used for drug-delivery applications because of its beneficial physicochemical properties, long safety record, and reliable commercial supply.

Materials and equipment innovations have advanced tablet coating from sugar to copolymers and simplified pharma production.

Industrial-scale continuous API manufacturing may offer cost and safety benefits.

As pharma models changed during the past 40 years, contract manufacturing capacity and services evolved to meet demand.

Polymers and surfactants impact stability and long-term performance.

Excipients play a key role in the development in emerging dosage forms but attention to quality is crucial.

BASF plans to build a new world-scale ibuprofen production plant in Ludwigshafen and expand ibuprofen capacities at its Bishop, Texas plant.

The company added new products to its InfinityLab LC Series which will be showcased at HPLC 2017 in Prague.

SK Biotek plans to operate the Swords, Ireland API manufacturing facility as a contract development and manufacturing site.

Sartorius Stedim Biotech combined the company’s ambr 15 bioreactor system with the Nova BioProfile FLEX2 cell culture analyzer for laboratory experiments.

Advances in chemical synthesis are enabling greener, more cost-efficient processes for API manufacturing.